Literature DB >> 30443317

Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy.

H Guadalajara Labajo1, M León Arellano1, J Vaquero Crespo2, I Valverde Núñez3, D García-Olmo1.   

Abstract

Constipation in spinal cord injury patients is a frequent complication that leads to a reduction of quality of life, extensive psychological and economic strain on patients and healthcare systems. We report a 58-year-old man with an incomplete SCI secondary to L1 vertebral fracture, presented gait disorder with neurogenic bowel and bladder dysfunction. He received 300 million autologous mesenchymal stromal cells (MSC) in the subarachnoid space by lumbar puncture. After the third administration of MSC the patient had an important improvement in almost every functional scale of spinal cord injury, especially in the Krogh's Neurogenic Bowel Dysfunction scale. Our present observation supports recent clinical findings about the benefit of autologous stem cell therapy for the improvement of bowel dysfunction in patients suffering spinal cord injury.

Entities:  

Year:  2018        PMID: 30443317      PMCID: PMC6232283          DOI: 10.1093/jscr/rjy300

Source DB:  PubMed          Journal:  J Surg Case Rep        ISSN: 2042-8812


INTRODUCTION

Neurogenic bowel dysfunction includes constipation, abdominal pain and fecal incontinence, this are frequent complications of spinal cord injury (SCI). Severe constipation could be present in more than 30% of this patient. Other complications include neuropathic and musculoskeletal pain, pressure ulcers, problematic spasticity and urinary tract infections. The patients with SCI have delayed colonic motility and anorectal dysfunction resulting in functional obstruction and constipation. This may be caused by changes in descending modulation from the central or sympathetic nervous systems [1]. Treatment include conservative management when possible, however, surgical procedures such as a colostomy may be indicated. Despite recent advances in the treatment of neurogenic bowel dysfunction, a significant proportion of subjects with SCI continue to have severe symptoms [2]. Neuroregenerative strategies to treat patients with SCI, aim to replace the damaged cells, axons and circuits in the spinal cord, by either modifying the injury environment to stimulate endogenous regeneration or cell transplantation [3]. It has been hypothesized that the therapeutic effect of stem cells may be due to their immunoregulatory and anti-inflammatory properties, which may work together to accelerate healing [4]. Recently, cell therapy with autologous bone marrow mesenchymal stromal cells (MSCs) supported in autologous plasma has been associated to a clear and early improvement in symptoms of neurogenic bowel dysfunction. This finding has been reported when MSCs were transplanted into an injured zone of SCI [5] or after repeated administration of MSCs in subarachnoid space by lumbar puncture [6]. However, in these studies, objective data provided by anorectal explorations were not shown. In this report, we show by the first time, objective data about the functional anorectal modifications occurred after cell therapy in a patient with SCI.

CASE REPORT

A 58-year-old man with an incomplete SCI (ASIA C and neurological level at Th12) secondary to L1 vertebral fracture (Fig. 1), presented a 32-year history of gait disorder with neurogenic bowel and bladder dysfunction.
Figure 1:

MRI: spinal cord injury secondary to L1 vertebral fracture.

MRI: spinal cord injury secondary to L1 vertebral fracture. The patient had undergone several years of rehabilitation without improvement in his neurological symptoms. Intermittent bladder catheterization was used for urinary dysfunction and presented a severe constipation with a defecation frequency every week with the need of laxatives and digital evacuation.

Preoperative test

Initial physical examination revealed an atonic anal sphincter and a pelvic floor descent. An endorectal ultrasound was done, the external anal sphincter showed no lesions and a thin internal sphincter without mobility. Anorectal manometry showed basal resting pressure and anal squeeze pressure of 35–40 mmHg. Also, a hypotonic internal anal sphincter, lack of external anal sphincter contraction and a complete absence of rectal sensibility due to distension despite high volumes. Rectoanal inhibitory reflex was present. Dynamic MRI: Important rectal prolapse and pelvic floor descent. The evacuation after the introduction of the endorectal contrast was incomplete. (Fig. 2)
Figure 2:

Dynamic MRI: incomplete contrast evacuation.

Dynamic MRI: incomplete contrast evacuation. In the Krogh´s Neurogenic Bowel Dysfunction scale [7] presented a Severe condition with 19 points. Previous authorization of the ethic committee and a signed informed consent, the patient was included in a clinical trial to study the effects of cell therapy in patients suffering SCI (EudraCT 2014-005613-24).

Cell therapy medicament

We used a cell therapy medicament (NC1) currently approved as a medicament under clinical investigation by the AEMPS (PEI No. 12–141). It consists of autologous MSCs and autologous plasma as its excipient. For culture of MSCSs, 50 mL of bone marrow was aspirated under aseptic conditions from the iliac bones and sent to a cleanroom for culture and expansion under good manufacturing practice (GMP). The cultures were maintained at 37°C in a humidified 5% CO2 atmosphere for 3 days, after which non-adherent cells were removed by replacing the medium. When the cultures approached confluence (90–100%), adherent cells were detached by treatment with trypsin/ethylenediamine tetraacetic acid (EDTA) solution (BioWhittaker-Lonza). Criteria for the administration of MSCs included a viability >95%, absence of microbial contamination (bacteria, fungus, virus or mycoplasma), expression of CD105, CD90, HLA I, CD73 and CD166 for more than 90% of cells, and absence of CD34, CD80, HLA II, CD45 and CD31 (expression of each <5%), as assessed by flow cytometry.

Surgery description

He received 300 million autologous MSCs in the subarachnoid space by lumbar puncture, at a dose of 100 millions every 3 months in the Cell Therapy Unit.

Postoperative test

After the third administration, the patient had an important improvement in almost every functional scale of spinal cord injury, especially in the Krogh´s Neurogenic Bowel Dysfunction scale, at this point with a Minor Bowel Dysfunction grade with 6 points. Six months after first treatment, an anorectal manometry was done, showing an increased basal resting pressure of 82 mmHg and anal squeeze pressure of 105.4 mmHg. Slight improvement in rectal sensibility. Rectoanal inhibitory reflex was present. Dynamic MRI: Important rectal prolapse and pelvic descent without changes. The evacuation after the introduction of the endorectal contrast was complete (Fig. 3).
Figure 3:

Dynamic MRI: complete contrast evacuation.

Dynamic MRI: complete contrast evacuation. The patient referred less soiling, but defecatory diary is not evaluable due to the regular use of a rectal irrigator device.

DISCUSSION

Constipation in spinal cord injury patients is a frequent complication that leads to a reduction of quality of life, extensive psychological and economic strain on patients and healthcare systems [8]. When conservative treatments fail to improve the constipation, Malone anterograde continence enema and sacral anterior root stimulator implantation, and even more aggressive procedures like colostomy, ileostomy, must be considered [9]. Our present observation supports recent clinical findings about the benefit of autologous stem cell therapy for the improvement of bowel dysfunction in patients suffering SCI [5, 6]. The mechanism of improvement is difficult to establish, but the possibility that MSCs may act through the release of neurotrophic factors has been pointed out [6]. In any case, the improvement in neurogenic bowel dysfunction after cell therapy, at least using autologous bone marrow MSCs supported in autologous plasma is configured as a virtually constant finding [5, 6] that can be objectified not only by the application of functional scales, but also by objective data for anorectal exploration, as we show in our present case (Table 1).
Table 1

Results before and after treatment.

Before treatmentAfter treatment
Manometry
 Basal resting pressure35–40 mmHg82 mmHg
 Anal squeeze pressure35–40 mmHg105.4 mmHg
 Rectal sensibilityAbsencePresent
 Rectoanal inhibitory reflexPresentPresent
Dynamic MRI
 Contrast evacuationIncompleteComplete
 M-line descent9 cm9 cm
Krogh´s Neurogenic Bowel Dysfunction scale19 pts6 pts
Results before and after treatment. In conclusion, the administration of autologous MSCs into subarachnoid space is a simple and safe procedure [6] that should be considered for the treatment of severe constipation in SCI patients.
  9 in total

Review 1.  Anorectal physiology following spinal cord injury.

Authors:  A C Lynch; A Anthony; B R Dobbs; F A Frizelle
Journal:  Spinal Cord       Date:  2000-10       Impact factor: 2.772

2.  International standards for neurological classification of spinal cord injury (revised 2011).

Authors:  Steven C Kirshblum; Stephen P Burns; Fin Biering-Sorensen; William Donovan; Daniel E Graves; Amitabh Jha; Mark Johansen; Linda Jones; Andrei Krassioukov; M J Mulcahey; Mary Schmidt-Read; William Waring
Journal:  J Spinal Cord Med       Date:  2011-11       Impact factor: 1.985

3.  The artificial somato-autonomic reflex arch does not improve lower urinary tract function in patients with spinal cord lesions.

Authors:  Mikkel Mylius Rasmussen; Yazan F Rawashdeh; Dorte Clemmensen; Hatice Tankisi; Anders Fuglsang-Frederiksen; Klaus Krogh; Peter Christensen
Journal:  J Urol       Date:  2014-08-23       Impact factor: 7.450

Review 4.  Optimal treatment for severe neurogenic bowel dysfunction after chronic spinal cord injury: a decision analysis.

Authors:  J C Furlan; D R Urbach; M G Fehlings
Journal:  Br J Surg       Date:  2007-09       Impact factor: 6.939

5.  Neurogenic bowel dysfunction score.

Authors:  K Krogh; P Christensen; S Sabroe; S Laurberg
Journal:  Spinal Cord       Date:  2005-12-13       Impact factor: 2.772

6.  Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury.

Authors:  Jesús Vaquero; Mercedes Zurita; Miguel A Rico; Celia Bonilla; Concepción Aguayo; Cecilia Fernández; Noemí Tapiador; Marta Sevilla; Carlos Morejón; Jesús Montilla; Francisco Martínez; Esperanza Marín; Salvador Bustamante; David Vázquez; Joaquín Carballido; Alicia Rodríguez; Paula Martínez; Coral García; Mercedes Ovejero; Marta V Fernández
Journal:  Cytotherapy       Date:  2017-01-06       Impact factor: 5.414

7.  Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial.

Authors:  Mariano García-Arranz; Maria Dolores Herreros; Carolina González-Gómez; Paloma de la Quintana; Héctor Guadalajara; Tihomir Georgiev-Hristov; Jacobo Trébol; Damián Garcia-Olmo
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

Review 8.  Spinal cord injuries: how could cell therapy help?

Authors:  Anna Badner; Ahad M Siddiqui; Michael G Fehlings
Journal:  Expert Opin Biol Ther       Date:  2017-03-27       Impact factor: 4.388

9.  An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial.

Authors:  Jesús Vaquero; Mercedes Zurita; Miguel A Rico; Celia Bonilla; Concepcion Aguayo; Jesús Montilla; Salvador Bustamante; Joaquin Carballido; Esperanza Marin; Francisco Martinez; Avelino Parajon; Cecilia Fernandez; Laura De Reina
Journal:  Cytotherapy       Date:  2016-06-13       Impact factor: 5.414

  9 in total
  2 in total

Review 1.  Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials.

Authors:  Emmanouil I Damianakis; Ioannis S Benetos; Dimitrios Stergios Evangelopoulos; Aikaterini Kotroni; John Vlamis; Spyridon G Pneumaticos
Journal:  Cureus       Date:  2022-04-28

2.  The effect of the therapy of "combination 3 methods progression" in patients with neurogenic bowel dysfunction (constipated type): Study protocol for a randomized controlled trial.

Authors:  Qing Li; Yin-Li Shen; Yun-Lan Jiang; Dong-Shuang Li; Song Jin
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.